Home›Cidofovir›Cidofovir + Emtricitabine And Tenofovir Alafenamide

Does Cidofovir Interact with Emtricitabine And Tenofovir Alafenamide?

Cidofovir and Emtricitabine And Tenofovir Alafenamide have a moderate drug interaction according to U.S. FDA drug labeling data. Coadministration may increase concentrations of FTC, tenofovir, and cidofovir due to competition for active tubular secretion. The mechanism involves competition for renal active tubular secretion. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity: Moderate
Emtricitabine And Tenofovir Alafenamide Class: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Management: Monitor for effects
Data Source: U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Cidofovir and Emtricitabine And Tenofovir Alafenamide occurs because competition for renal active tubular secretion. Clinically, this means coadministration may increase concentrations of ftc, tenofovir, and cidofovir due to competition for active tubular secretion. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.

What To Tell Your Doctor or Pharmacist

If you are taking Cidofovir and your doctor is considering prescribing Emtricitabine And Tenofovir Alafenamide (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Ask whether any dosage adjustments are needed
Never stop or change either medication without first consulting your healthcare provider

💊 Cidofovir+💊 Emtricitabine And Tenofovir Alafenamide(Descovy)

Severity & Interaction Details

🟡

moderate

Be aware — moderate interaction

Documented interaction with manageable risk. May require dose adjustment or monitoring.

Severity scale

MinorContra

On record

Yes

Drug A class

—

Drug B class

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Source

NLP:emtricitabine and tenofovir alafenamide

What this means in plain English

Coadministration may increase concentrations of FTC, tenofovir, and cidofovir due to competition for active tubular secretion.

About Cidofovir and Emtricitabine And Tenofovir Alafenamide

Emtricitabine And Tenofovir Alafenamide is a Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor. Emtricitabine And Tenofovir Alafenamide is also sold under the brand name Descovy. Cidofovir is given by intravenous (IV) infusion, whereas Emtricitabine And Tenofovir Alafenamide is taken by mouth. Both Cidofovir and Emtricitabine And Tenofovir Alafenamide carry an FDA boxed warning — the agency's most serious safety designation.

What the FDA label says

"Competition for renal active tubular secretion"

📖 Source: NLP:emtricitabine and tenofovir alafenamide

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Cidofovir and Emtricitabine And Tenofovir Alafenamide against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.